PharmaTutor Magazine - March 2016 is released | Subscribe today
Off-label use of drug and patients suffering : whom to blame?
As per USFDA, The drug label of FDA-approved drugs gives information about the drug, including the approved doses and how it's to be given to treat the medical condition for which it was approved. When a drug is used in a way that is different from that described in the FDA-approved drug label, it is said to be an "off-label" use. This can mean that the drug is:
· Used for a different disease or medical condition.
· Given in a different way (such as by a different route)
· Given in a different dose.
Off-label is also called "non-approved" or "unapproved" use of a drug.
The recent cases of Avastin are example of same. It is noted that opthalmic injection of Avastin leads to blindness in some patients which is not approved for intra-vitrieal use in India.
Roche clearly told to ET, “We would like to reiterate that Avastin (bevacizumab) has not been approved for intraocular use by the US FDA, European Medicines Agency or the government of India.”
Use of off-label drug may improve affordable access to innovative medicines largely because of its flexibility. While pharmaceutical companies are prohibited from advertising a drug for any unapproved purposes, physicians are free to use it for any purposes that in their professional judgement are considered safe and effective. This practice can be adopted by almost any country in the world: in the United States, for example, off-label use of drugs is very common in cancer treatment. 
Off-label use of drugs can also reduce cost of therapies.
But the question still remains whom to blame?
1. Economic Times: